| Date Filed | Type | Description |
| 08/10/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 06/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits Interac... |
| 06/09/2023 |
4
| Wills Robert James (Director) has filed a Form 4 on Milestone Pharmaceuticals Inc.|
Txns:
| Granted 30,000 options to buy
@ $3.86, valued at
$115.8k
|
|
| 06/09/2023 |
4
| TOMSICEK MICHAEL JOHN (Director) has filed a Form 4 on Milestone Pharmaceuticals Inc.|
Txns:
| Granted 30,000 options to buy
@ $3.86, valued at
$115.8k
|
|
| 06/09/2023 |
4
| Pasternak Richard C (Director) has filed a Form 4 on Milestone Pharmaceuticals Inc.|
Txns:
| Granted 30,000 options to buy
@ $3.86, valued at
$115.8k
|
|
| 06/09/2023 |
4
| Liebert Debra K. (Director) has filed a Form 4 on Milestone Pharmaceuticals Inc.|
Txns:
| Granted 30,000 options to buy
@ $3.86, valued at
$115.8k
|
|
| 06/09/2023 |
4
| Giles Lisa M. (Director) has filed a Form 4 on Milestone Pharmaceuticals Inc.|
Txns:
| Granted 30,000 options to buy
@ $3.86, valued at
$115.8k
|
|
| 06/09/2023 |
4
| Fischer Seth H. Z. (Director) has filed a Form 4 on Milestone Pharmaceuticals Inc.|
Txns:
| Granted 30,000 options to buy
@ $3.86, valued at
$115.8k
|
|
| 05/31/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/15/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/28/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/31/2023 |
8-K
| Quarterly results |
| 03/29/2023 |
8-K
| Quarterly results |
| 03/29/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/28/2023 |
8-K
| Quarterly results |
| 03/27/2023 |
8-K
| Quarterly results |
| 03/24/2023 |
4
| RTW INVESTMENTS, LP (10% Owner) has filed a Form 4 on Milestone Pharmaceuticals Inc.|
Txns:
| Disposed of 1,059,000 shares
@ $0 |
|
| 03/23/2023 |
4
| Fischer Seth H. Z. (Director) has filed a Form 4 on Milestone Pharmaceuticals Inc.|
Txns:
| Granted 42,000 options to buy
@ $3.45, valued at
$144.9k
|
|
| 03/23/2023 |
3
| Fischer Seth H. Z. (Director) has filed a Form 3 on Milestone Pharmaceuticals Inc. |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/07/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 02/14/2023 |
SC 13G/A
| ORBIMED CAPITAL LLC reports a 0% stake in Milestone Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in Milestone Pharmaceuticals Inc. |
| 02/14/2023 |
SC 13G/A
| Venrock Healthcare Capital Partners III, L.P. reports a 6.4% stake in Milestone Pharmaceuticals Inc. |
| 02/14/2023 |
SC 13G/A
| Boxer Capital, LLC reports a 2% stake in Milestone Pharmaceuticals Inc. |
| 02/14/2023 |
SC 13G/A
| Ikarian Capital, LLC reports a 1.3% stake in Milestone Pharmaceuticals Inc. |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/19/2023 |
SC 13G
| GOLDMAN SACHS GROUP INC reports a 8% stake in MILESTONE PHARMACEUTICALS INC. |
|